Medicine and Dentistry
Patient
100%
Gallium 68
76%
Inpatient
75%
Ligand
67%
Biological Marker
54%
Positron Emission Tomography
49%
Prostate Cancer
47%
Non Muscle Invasive Bladder Cancer
45%
Assessment
40%
Prostatectomy
33%
Therapeutic Procedure
30%
Association
30%
Bladder Cancer
29%
Magnetic Resonance Imaging
28%
Tissues
28%
Recurrent Disease
27%
Lymphocyte
27%
Stone
27%
Prostate Specific Membrane Antigen
27%
Neutrophil
27%
Systemic Therapy
27%
Castration Resistant Prostate Cancer
27%
Diagnosis
25%
Combination Therapy
23%
Survival
22%
Neoplasm
21%
Urology
20%
Decision Making
19%
PET-MRI
18%
Radiation Therapy
17%
Biochemical Recurrence
17%
Overall Survival
16%
Stent
16%
Surgery
16%
Radioactive Tracer
15%
Histology
15%
Hormone
15%
PET-CT
15%
Hospital Management
15%
Cystectomy
14%
Germinoma
13%
Body Mass Index
13%
Lymphocyte Antigen Receptor
13%
Antigen
13%
Protein Expression
13%
Radioligand
13%
Seasonal Variation
13%
Cancer Prognosis
13%
Diet
13%
Monocyte
13%
Ureter Stone
13%
Clinical Significance
13%
Patient Selection
13%
Cancer Registry
13%
Meta-Analysis
13%
Systematic Review
13%
Lutetium 177
13%
Gallium
13%
Cytoreductive Surgery
13%
Joint
13%
Diagnostic Performance
13%
Lymph Node Metastasis
13%
Prostate Specific Antigen
11%
Lesion
11%
Analysis
11%
Morphology
10%
Nephrostomy
9%
Response Evaluation Criteria in Solid Tumors
9%
Evaluation Study
9%
Diseases
9%
Age
8%
Malignant Neoplasm
8%
Risk Stratification
8%
Follow up
7%
Hydronephrosis
6%
Muscle Invasive Bladder Cancer
6%
Polyp
6%
Prognosis
6%
Kidney
6%
Urine
6%
Dietary Supplement
6%
Fluorine-18
6%
Progression Free Survival
6%
Pelvis
6%
Urinary Diversion
6%
Tumor Diagnosis
5%
Incidence
5%
Metastatic Carcinoma
5%
Standardized Uptake Value
5%
Accuracy
5%
Lymph Node
5%
Prospective Study
5%
Transitional Cell Carcinoma
5%
Specimen
5%
Nursing and Health Professions
Gallium 68
27%
Ligand
27%
Castration Resistant Prostate Cancer
27%
Positron Emission Tomography
21%
Mean Standardized Uptake Value
15%
Parameters
15%
Combination Therapy
15%
Tumor Volume
15%
Systemic Therapy
13%
Lutetium 177
13%
Radioligand
13%
Overall Survival
13%
Conjugate
11%
Prostate Specific Antigen
11%
Nuclear Magnetic Resonance Imaging
9%
Response Evaluation Criteria in Solid Tumors
9%
Diseases
7%
Evaluation Study
7%